Abstract
IntroductionThis study was undertaken to compare decisions about medicines innovation made by two Canadian organizations, the Therapeutic Products Directorate (TPD) and the Human Drug Advisory Panel (HDAP), with those made by similar organizations in other countries. MethodsAssessments by TPD and HDAP were compared to those made by the Food and Drug Administration (FDA) and the drug bulletin Prescrire International, respectively. ResultsBetween 2004 and 2009 the TPD gave priority reviews to 46 of 137 (34%) products compared to 71 of 145 drugs (49%) by the FDA (p=0.011). Of 109 drugs in common the two agreed on the review status in 88 (weighted Kappa=0.606). In the same time period HDAP categorized 12 of 120 (10%) drugs as innovative while Prescrire did the same for 49 of 624 (8%) new drugs and new indications for older drugs (p=0.4664). Of 84 drugs in common the two agreed on the evaluation for 70 (weighted Kappa=0.319). DiscussionDifferences between the different organizations may be due to a variety of factors. These differences have significant policy implications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
